The NCI’s CP-CTNet aims to conduct early phase clinical trials to evaluate the safety and efficacy of cancer preventive agents. This grant supports CP-CTNet Sites in leading these trials and analyzing the data for further insights into cancer prevention mechanisms. Research will focus on molecular targets, biological events related to cancer development, and potential response markers. The grant also emphasizes phases 0, I, and II clinical trials. Applications should align with CP-CTNet goals to contribute to advancements in cancer prevention research. Closing date for applications is August 29, 2019.
Opportunity ID: 317696
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-19-031 |
| Funding Opportunity Title: | Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 28, 2019 |
| Last Updated Date: | Jun 28, 2019 |
| Original Closing Date for Applications: | Aug 29, 2019 |
| Current Closing Date for Applications: | Aug 29, 2019 |
| Archive Date: | Oct 04, 2019 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses State governments Public and State controlled institutions of higher education Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see the funding announcement for eligibility details |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative the Cancer Prevention Clinical Trials Network (CP-CTNet). The CP-CTNet goals are as follows: – Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; – Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. – Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response. CP-CTNet consists of two types of components: – Several CP-CTNet Sites (supported under this FOA and its predecessor RFA-CA-18-029); and – One CP-CTNet Data Management, Auditing, and Coordinating Center (covered by previously issued RFA-CA-18-030). The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as in the management and analysis of the data. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-031.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | FORMS-E | PKG00252423 | Jul 29, 2019 | Aug 29, 2019 | View |
Package 1
Mandatory forms
317696 RR_SF424_2_0-2.0.pdf
317696 PHS398_CoverPageSupplement_4_0-4.0.pdf
317696 RR_OtherProjectInfo_1_4-1.4.pdf
317696 PerformanceSite_2_0-2.0.pdf
317696 RR_KeyPersonExpanded_2_0-2.0.pdf
317696 RR_Budget_1_4-1.4.pdf
317696 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
317696 RR_SubawardBudget30_1_4-1.4.pdf
317696 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
